Avacta enters significant partnership with OncoSec Medical

05:45 EST 22 Jan 2018 | Proactive Investors

Alastair smith, chief executive of Avacta Group Plc’s (LON:AVCT), tells Proactive that interest in their Affimer technology continues to grow following the announcement of another collaboration agreement - this time with OncoSec Medical Inc (NASDAQ:ONCS).

OncoSec has developed a gene delivery technology called ImmunoPulse which it wants to use to deliver Affimers - including Avacta’s PD-L1 inhibitor - into tumour cells and other tissues.

The companies plan to then demonstrate efficacy of the Affimers in a relevant in vivo tumour model.

Original Article: Avacta enters significant partnership with OncoSec Medical


More From BioPortfolio on "Avacta enters significant partnership with OncoSec Medical"

Quick Search


Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...